AC Immune S.A.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Martin Zügel
- Full Time Employees
- 106
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building B Lausanne VD Switzerland 1015
- IPO Date
- Sep 23, 2016
- CIK
- 0001651625
- Website
- acimmune.com
- Similar Companies
- Business
- AC Immune SA (ACIU), a clinical-stage biopharmaceutical company founded in 2003 and headquartered in Lausanne, Switzerland, discovers, designs and develops precision medicines, therapeutics and diagnostics targeting misfolded proteins underlying neurodegenerative diseases including Alzheimer's disease, Parkinson's disease and NeuroOrphan indications. The company leverages its proprietary SupraAntigen® and Morphomer® technology platforms to advance a diversified pipeline encompassing active immunotherapies such as ACI-24.060 (anti-amyloid beta for Alzheimer's, partnered with Janssen), ACI-7104.056 (anti-alpha-synuclein for early Parkinson's), and ACI-35.030 (anti-Tau for Alzheimer's, partnered with Lilly); therapeutic antibodies; small molecule inhibitors including ACI-19764 (NLRP3), Morphomer®-Tau and alpha-synuclein aggregation inhibitors, and Morphomer®-antibody drug conjugates (morADCs); as well as diagnostic agents like Tau PET tracers. AC Immune operates globally with a focus on clinical-stage programs in Phase 2 and preclinical advancement, deriving validation and non-dilutive funding from strategic alliances with pharmaceutical leaders including Janssen, Takeda and Eli Lilly, which provide over $4.5 billion in potential milestones plus royalties. In September 2025, the company sharpened its pipeline focus on three Phase 2 active immunotherapies and priority small molecule programs targeting NLRP3, Tau and alpha-synuclein, implementing operational efficiencies including a 30% workforce reduction to extend cash runway into Q3 2027; near-term catalysts include interim Phase 2 data from ACI-7104.056 (H2 2025), ACI-24.060 (H1 2026), IND filing for ACI-19764 (H2 2025) and Morphomer® lead declarations.
Company News
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
AC Immune (ACIU) Beats Q2 Earnings and Revenue Estimates
AC Immune First Half 2026 Financial and Corporate Update
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease
AC Immune (ACIU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care
AC Immune (ACIU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates
AC Immune First Quarter 2026 Financial and Corporate Updates
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know
Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?
Why AC Immune Stock Zoomed Almost 15% Higher Today
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
AC Immune (ACIU) Upgraded to Buy: Here's Why
Is AC Immune (ACIU) Outperforming Other Medical Stocks This Year?